KidneyAustralian adults with biomedical signs of CKD, 2022 to 2024
Australian Institute of Health and Welfare
Impact, investment and supportWhen the gap closes,
When the gap closes,
the whole system can see.
KidneyMate is early, so we do not claim proven outcomes. We are building the patient-facing connective layer between daily self-management and clinical conversations, then testing the value properly.
Research first · Proof next
Scroll to explore ↓Adults living with CKD worldwide in 2023
GBD CKD Collaborators, The LancetPlanned clinical validation research
For patients
From managing alone to managing supported.
The daily work does not disappear with an app. What can change is how it feels to carry: one routine instead of fragments, patterns a person can see, and a clearer conversation with someone accountable.
Published studies of supported digital self-management give grounds for optimism. Testing KidneyMate itself is the work ahead.
For clinicians
From reconstruction to review.
Structured between-visit context could let a consultation begin from evidence: trends since last visit, patient-led priorities and inspectable flags rather than memory alone.
The advantage is not simply more data. It is information shaped for accountable human judgement.
For the health system
Early attention is the affordable end of kidney care.
CKD sits on a steep cost gradient. The mechanism we intend to test is practical: earlier sight of changing patterns, better-prepared conversations and continuity that scales without simply adding clinic hours.
We will not attach an invented dollar figure or claim a saved admission before evidence exists.
Claims on this site stop where the evidence stops.
A focused ecosystem.
Trust as infrastructure.
The moat is not a feature race. It is a clinically responsible pathway, patient trust, workflow fit, longitudinal context and evidence earned in the right order.
Designed in the detailsThe work behind
The work behind
the calm.
2025
Research foundations
University work in patient-generated health data becomes the seed of KidneyMate.
2026
Framework and pilot readiness
The conceptual framework, working prototype and governed pilot preparation mature together.
2027
Clinical validation research
Formal evaluation of usability, interpretability, relevance and workflow fit.
2027 to 2028
Deeper integration
The clinician view matures toward health-system pathways, guided by what validation teaches.
Back a more connected
kidney-care future.
We welcome conversations with aligned investors, funders, research partners and supporters.
View investment opportunities ↗